Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Public ClinicalTrials.gov record NCT05330429. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC). The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).
Study identification
- NCT ID
- NCT05330429
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Interventions
- Magrolimab Drug
- Bevacizumab Drug
- Irinotecan Drug
- Fluorouracil Drug
- Leucovorin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 7, 2022
- Primary completion
- Jun 25, 2024
- Completion
- Jun 25, 2024
- Last update posted
- Jun 30, 2025
2022 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope ( City of Hope National Medical Center, City of Hope Medical Center ) | Duarte | California | 91010 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Stanford Cancer Center | Palo Alto | California | 94305 | — |
| Torrance Memorial Physician Network | Redondo Beach | California | 90277 | — |
| University of California Los Angeles (UCLA) | Santa Monica | California | 90095 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | — |
| Fort Wayne Medical Oncology and Hematology, Inc. | Fort Wayne | Indiana | 46845 | — |
| University of Kansas | Westwood | Kansas | 66205 | — |
| University of Michigan | Ann Arbor | Michigan | 48106 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Hematology Oncology Associates of Central New York, PC | East Syracuse | New York | 13057 | — |
| AdventHealth | Rochester | New York | 14642 | — |
| Pennsylvania Hospital | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 327203 | — |
| Texas Oncology | Dallas | Texas | 75246 | — |
| Baylor College of Medicine Medical Center | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists, PC | Arlington | Virginia | 22205 | — |
| Seattle Cancer Care Alliance (SCCA) | Seattle | Washington | 98103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05330429, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2025 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05330429 live on ClinicalTrials.gov.